Literature DB >> 18061688

Treatment of yellow fever.

Thomas P Monath1.   

Abstract

Yellow fever (YF) is a life-threatening mosquito-borne flaviviral hemorrhagic fever (VHF) characterized by severe hepatitis, renal failure, hemorrhage, and rapid terminal events with shock and multi-organ failure. A live, attenuated vaccine (YF 17D), in wide use for over 60 years, causes a disease identical to wild-type virus at an incidence of 2.5x10(-6). Our current understanding of the pathogenesis and treatment of YF (described in this brief review) is derived from studies of animal models (macaques, hamsters) that reproduce the features of human YF and from descriptive studies of human cases of naturally acquired and vaccine-associated VHF. The least understood, but potentially most important terminal events appear to be due to 'cytokine storm' and represent a potential target for therapeutic interventions. Areas for future study include dissection of cytokine-mediated events in animal models, the pathogenic role of the profound neutrophilia that occurs pre-terminally, the (pathological) role of adaptive immune clearance in pathogenesis, and treatments directed at cytokine storm. Antibody, interferon-alpha, polyICLC and other immune modulators are highly effective when administered before or within a narrow time window after infection, but are ineffective when given after the infection is established. A few antivirals have been evaluated (ribavirin, tiazofurin, carboxamide, pyrazoline compounds). Ribavirin has been used successfully to treat hamsters when the drug is given at high doses up to 2 days after virus infection (shortly before liver infection), but has not shown promise in nonhuman primate models. Future work should focus on evaluating higher doses of ribavirin alone or in combinations with potentially synergistic drugs, including interferons. Also specific inhibitors against other flaviviruses such as dengue virus should be investigated for potential pan-flavivirus activity since recent studies have shown that specific targets such as the flavivirus proteases and helicases are very similar in structure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061688     DOI: 10.1016/j.antiviral.2007.10.009

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  59 in total

1.  BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Authors:  Justin G Julander; Shanta Bantia; Brian R Taubenheim; Dena M Minning; Pravin Kotian; John D Morrey; Donald F Smee; William P Sheridan; Yarlagadda S Babu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 2.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

3.  A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Carol D Blair; John T Roehrig
Journal:  Vaccine       Date:  2012-03-13       Impact factor: 3.641

4.  Multiple dengue virus serotypes resistant transgenic Aedes aegypti fitness evaluated under laboratory conditions.

Authors:  Hewawasam Patuwatha Badathuruge Kalindu Dulanja Ramyasoma; Ranil Samantha Dassanayake; Menaka Hapugoda; Margareth L Capurro; Yasanthi Illika Nilmini Silva Gunawardene
Journal:  RNA Biol       Date:  2020-03-06       Impact factor: 4.652

5.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

6.  Effect of Myracrodruon urundeuva leaf lectin on survival and digestive enzymes of Aedes aegypti larvae.

Authors:  Thiago Henrique Napoleão; Emmanuel Viana Pontual; Thâmarah de Albuquerque Lima; Nataly Diniz de Lima Santos; Roberto Araújo Sá; Luana Cassandra Breitenbach Barroso Coelho; Daniela Maria do Amaral Ferraz Navarro; Patrícia Maria Guedes Paiva
Journal:  Parasitol Res       Date:  2011-07-07       Impact factor: 2.289

Review 7.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

8.  Docking Studies of Adenosine Analogues with NS5 Methyltransferase of Yellow Fever Virus.

Authors:  Kh Dhanachandra Singh; Palani Kirubakaran; S Manikandaprabhu; S Nagamani; P Srinivasan; M Karthikeyan
Journal:  Indian J Microbiol       Date:  2011-08-09       Impact factor: 2.461

9.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.